The impact of matrix metalloproteinase (MMP) on left ventricular (LV) remodeling and heart failure events is unresolved in patients with hypertrophic cardiomyopathy (HCM).
ypertrophic cardiomyopathy (HCM) is a primary myocardial disease that has been defined as left ventricular (LV) hypertrophy without other cardiovascular pathologies, and it is due to genetic abnormalities in sarcomeric protein genes. 1- 3 The clinical and morphological features are diverse and the natural history varies from an asymptomatic and benign clinical course to heart failure, stroke and sudden premature death. [4] [5] [6] [7] LV systolic impairment secondary to LV remodeling occurs in approximately 5-10% of adult patients with HCM and it is related to refractory heart failure and a poor prognosis. [8] [9] [10] [11] [12] However, the precise mechanisms of LV remodeling under these conditions are undetermined. It is well known that extracellular matrix plays an important role in LV remodeling after myocardial infarction, in which matrix metalloproteinases (MMPs) are involved. 13- 15 The activation of MMPs that affect extracellular collagen matrix is linked to adverse LV remodeling and related to a poor prognosis in patients with myocardial infarction. 16, 17 Although MMPs are also activated in patients with HCM, data about their involvement in LV remodeling and LV remodeling-related events (or heart failure events) are limited. 18- 21 Moreover, circulating levels of B-type natriuretic peptide (BNP) are a wellestablished predictor of outcome in patients with chronic heart failure associated with acquired cardiac disease. 22 Although BNP is often elevated and correlates with the severity of heart failure symptoms in patients with HCM, the clinical utility to predict heart failure events is limited because of the complex mechanism of their elevation. [23] [24] [25] [26] [27] Therefore, the purpose of this study was to elucidate the significance of MMPs levels in the LV remodeling process and the usefulness of it as a prognostic predictor of heart failure events in patients with HCM.
Methods

Patients
We retrospectively enrolled 41 patients with HCM who were diagnosed based on echocardiographic confirmation with a hypertrophied left ventricle (maximum wall thickness KITAOKA H et al.
≥15 mm) in the absence of systemic hypertension or other cardiac diseases (such as aortic stenosis or storage disease) that could produce the magnitude of such hypertrophy. 1,2 Clinical, electrocardiographic, echocardiographic characteristics and laboratory parameters were determined in all patients while they were clinically stable. Patients with renal failure (serum creatinine ≥2.0 mg/dl), myocardial infarction due to atherosclerotic coronary lesions, inflammatory disease or malignancy were excluded from the study. The Ethics Committee on Medical Research at our institution approved the study protocol and all patients provided written informed consent to participate.
Echocardiography
Echocardiographic images were acquired using a Sequoia 512 (Mountain View, CA, USA). The dimensions of the left ventricle and the left atrium were measured and the magnitude and distribution of LV hypertrophy were assessed from 2-dimensional images. The greatest wall thickness measured at any site in the left ventricle was regarded as the maximum thickness. The intraventricular pressure gradient was also measured using a continuous-wave Doppler under basal conditions, and an LV outflow gradient of ≥30 mmHg was considered significant. LV systolic impairment was defined as a LV ejection fraction (LVEF) ≤50% by modified Simpson's method.
Hematological Measurements
Peripheral venous blood samples were collected from the antecubital vein from patients who had remained supine for at least 15 min without discontinuing drug treatment. Plasma was obtained by centrifugation for 15 min at 3,500 × g. Aliquots were stored at -40°C to allow analysis. We measured plasma levels of MMP-2, MMP-9 and tissue inhibitor of metalloproteinase (TIMP)-1 using a commercially available one-step sandwich enzyme immunoassay kit (DAIICHI FINE CHEMICAL Co, Toyama, Japan). Briefly, in those kits, monoclonal antibody to MMP-2 (clone 42-5D11, IgG1 isotype) specifically reacts with precursor and active forms of human MMP-2. Monoclonal antibody to MMP-9 (clone 56-2A4, IgG1 isotype) specifically reacts with precursor (92 kDa) and intermediate (83 kDa) forms of human MMP-9, but not with active human MMP-9 (67 kDa). Monoclonal antibody to TIMP-1 (clone 147-6D11, IgG1 isotype) specifically reacts with human TIMP-1. Plasma BNP levels were measured using an enzyme immunoassay (TOSOH II, TOSOH, Tokyo, Japan).
The estimated glomerular filtration rate (eGFR) was calculated as follows: eGFR =194 × age -0.287 × serum creatinine level -1.094 in men, and 194 × age -0.287 × serum creatinine level -1.094 × 0.739 in women.
Heart Failure Events
The initial clinical evaluation comprised hematological measurements and independent assessments of clinical status and functional capacity. Heart failure events were defined as death for progressive heart failure symptoms or admission for heart failure. The incidence of events was systematically assessed using available medical records and telephone interviews with the patients and/or referring physicians.
Statistical Analysis
Data are presented as mean ± SD. Correlations between laboratory findings and continuous variables were evaluated using linear regression analysis. Because the distribution of values of biomarkers was skewed, the log transformation of values was used. Variables between 2 groups were compared using the Wilcoxon rank-sum test.
Comparison of nominal variables expressed as proportions was performed using Fisher's exact test.
Univariate logistic regression analysis was used to provide the prognostic significance of clinical and echocardiographic parameters and biomarkers, and then multivariate stepwise logistic regression analysis (considered as factors of P value less than 0.1) was done. For logistic regression analysis, all levels of biomarkers were calculated in blocks of 100. A receiver operating characteristics (ROC) curve analysis was constructed for the utility of MMPs to predict the prognosis. These cut-off points were identified as the point on the curve showing the highest combination of sensitivity and specificity and used for analysis of event-free curves using KaplanMeier estimates. A comparison of curves was made by the Log-rank test. A P level of <0.05 was considered to indicate statistical significance. Data were statistically analyzed using JMP version 7.0 software (SAS Institute Inc, Cary, NC, USA). Table 1 shows the clinical and echocardiographic features of the study cohort. Male patients were dominant and most Ca antagonist, n (%) 9 (22) ACEI/ARB, n (%) 10 (24) Amiodarone, n (%) 4 (9) Diuretics, n (%) 8 (20) Echocardiographic characteristics
Results
Clinical, Echocardiographic and Laboratory Features in All Patients
Left atrial diameter (mm) 44.8±7.4
Maximum LV wall thickness (mm) 20.7±4.7
LV outflow gradient > -30 mmHg, n (%) 6 (15) NYHA, New York Heart Association; eGFR, estimated glomerular filtration rate; ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; LV, left ventricular; LVEF, LV ejection fraction.
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patients were either asymptomatic or mildly symptomatic (New York Heart Association (NYHA) class I or II). Six patients had LV outflow obstruction and 8 patients showed LV systolic impairment. The mean levels of MMP-2, MMP-9 and TIMP-1 of all of the patients were 1,040±202 ng/ml, 337±182 ng/ml, and 180±32 ng/ml, respectively. Plasma BNP levels were 253± 187 pg/ml. The levels of MMP-1, MMP-9 and TIMP-1 were not related to age.
The MMP-2 levels were higher in patients with severe symptoms (NYHA III class) than in those with absent or mild symptoms (1,323±327 ng/ml vs 1,001±147 ng/ml, P=0.03). Levels of MMP-2 were also higher in patients with atrial fibrillation than in those with sinus rhythm (1,273±314 ng/ml vs 1,008±163 ng/ml, P=0.04).
Levels of MMP-2 were positively related to LV end- KITAOKA H et al.
systolic dimension and left atrial dilation, and negatively related to LVEF and LV wall thickness (Figure 1) . Levels of TIMP-1 were also associated with LV end-systolic dimension (r=0.44, P=0.004) and LVEF (r=-0.36, P=0.02). Moreover, MMP-2 levels were positively associated with those of BNP (Figure 2) . In contrast, MMP-9 levels were not significantly associated with echocardiographic parameters and plasma BNP levels.
Prognostic Parameters and LV Remodeling-Related Events
During a follow-up period of 3.2±0.7 years, 1 patient died of a stroke during hospitalization for progressive heart failure due to LV systolic impairment, and 5 required hospitalization for heart failure. Therefore, 6 patients (15%) reached the study end-points. Patients who experienced such events showed more reduced LV systolic function (LVEF =42±10% vs 66±8%, P=0.0003) and severe heart failure symptoms compared to patients who did not experience such events ( χ2 =19.5, P=0.0007). Univariate logistic regression analysis between clinical, echocardiographic parameters and biomarkers are shown in Table 2 . The levels of MMP-2 and TIMP-1 were significantly related to events among biomarkers. After adjusting for age, MMP-2 levels were still significantly related to events (relative risk =1.91, P=0.02). After making adjustments for eGFR, MMP-2 levels were marginally significant (relative risk = 1.63, P=0.06). By multivariate stepwise logistic analysis including atrial fibrillation, NYHA class, eGFR, LVEF and levels of MMP-2, LVEF was the only significant predictor of heart failure events (P=0.04). By using ROC curves, an 
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optimal cut-off was derived (MMP-2 =1,170 ng/ml), patients were divided into 2 categories. Patients with high MMP-2 levels showed poor prognosis compared to those with low MMP-2 levels (Figure 3) .
Discussion
The main finding of this study was that elevated levels of MMP-2 are associated with LV remodeling and poor prognosis in patients with HCM.
MMPs and LV Remodeling in Myocardial Infarction and
Heart Failure LV remodeling after myocardial infarction is related to progression to heart failure and a poor prognosis. Although the process of LV remodeling is complex, the balance between MMPs that degrade extracellular collagen matrix and TIMPs that inhibit MMPs is a key factor in extracellular matrix collagen regulation. 17 Kelly et al studied the relationships between LV remodeling and outcome and the levels of TIMP-1 and MMP-9 in 404 patients with acute myocardial infarction. 17 Their study showed that levels of TIMP-1 and MMP-9 correlate with echocardiographic parameters of LV remodeling and outcome. Therefore, measurement of MMP levels has been important for risk stratification in patients with myocardial infarction and heart failure.
Extracellular Collagen Matrix Regulation and LV Remodeling in HCM
HCM is a genetic cardiac disease in which a hypertrophied non-dilated left ventricle is characterized by various types of asymmetric wall thickening. 1-3 The clinical and morphological features of HCM are diverse and the natural history of the disease varies from an asymptomatic and benign clinical course to heart failure, stroke and sudden premature death. 4-7 A normal left ventricle with customary systolic function progresses to a dilated left ventricle with impaired systolic function (so-called dilated HCM or end-stage HCM) in 5-10% of adult patients with HCM. 8- 12 To clarify the mechanism of this, LV remodeling is important because this subgroup of patients develops refractory heart failure and a poor prognosis. Although a reliable predictor of LV systolic impairment has not been identified, myocardial fibrosis is one of the pathological characteristics of dilated HCM. 8 A recent study using cardiac magnetic resonance imaging has shown that delayed gadolinium enhancement, which is related to myocardial fibrosis, is more extended in patients with dilated HCM. 28 Therefore, extracellular collagen matrix regulation might play an important role in the changes required to evolve into systolic impairment.
Impaired collagenolysis such as an increase of TIMP-1, TIMP-2, TIMP-4, MMP-2 and MMP-9, and an increased deposition of collagen, have been reported in patients with HCM. 18-21 However, the relationship between MMPs and LV remodeling in HCM remains obscure. Noji et al studied the relationship between levels of MMPs and TIMPs and echocardiographic dimension in 28 HCM patients including 11 with dilated HCM. 19 They reported that MMP-2 was positively associated with LV dimension and negatively with LV systolic function in HCM. In contrast, Roldán et al studied the relationship between the levels of MMPs and echocardiographic/cardiac magnetic resonance findings in 67 HCM patients with preserved systolic function, and reported that the MMP-2 levels were negatively related to LV dimension. 20 Therefore, we studied the significance of the levels of MMP-2 (getalinase A), MMP-9 (gelatinase B) and TIMP-1, which are frequently used as biomarkers of collagen degradation in 41 patients including 8 patients with dilated HCM. We found that levels of MMP-2 and TIMP-1 were positively related to LV end-systolic dimension and negatively related to LV systolic function and maximum LV wall thickness. Although a precise explanation for this difference is difficult, patient selection and disease stage might probably be responsible for this difference. The patients in the study by Roldán et al were younger (49±14 years) than those in the study by Noji et al (57±1 years) and those in the present study (57±15 years). In addition, the study by Roldán et al did not include patients with LV systolic impairment. If patients with LV systolic impairment were excluded from the present study, MMP-2 levels would not have been found to be unrelated to LV end-systolic dimension (data were not shown in the text). Therefore, a further larger scale study is needed to investigate the roll of MMPs in the early process of LV remodeling in patients with HCM.
Biomarkers and LV Remodeling-Related Events in HCM
Biomarkers are molecules that are objectively measured by laboratory techniques, which can give us useful information about patients with cardiovascular disease, including HCM. Although MMP-2 levels did not reach statistical significance by multivariate logistic regression analysis including clinical, echocardiographic findings and biomarkers, to the best of our knowledge, this is first report in which elevated levels of MMP-2 were related to poor prognosis in patients with HCM. In patients with HCM, it is unclear whether even plasma BNP levels, which are established as the prognostic predictor for heart failure in patients with LV systolic impairment, are related to the heart failure events. Therefore, new biomarkers must be searched for in order to better manage patients with HCM. Although MMP-2 levels did not reach statistical significance in the multivariate logistic regression analysis, they were related to the pathophysiology of LV remodeling in HCM and we believe that MMP-2 is an important target as a useful biomarker in patients with HCM.
In experimental models of acute myocardial infarction, MMP inhibition is associated with attenuated LV dilatation and reduced wall stress. 29 Therefore, the early intervention for collagen turnover or MMPs levels might also prevent fibrosis/LV remodeling and improve the prognosis in HCM. 30 Extensive investigations on this viewpoint might be warranted in patients with HCM.
In conclusion, plasma levels of MMP-2 were related to LV systolic impairment and poor prognosis in patients with HCM. The present study results suggest that MMPs play an important role in LV remodeling in patients with HCM. Novel therapeutic strategies based on this perspective should be considered to improve the prognosis of patients with HCM.
Study Limitations
Several limitations are associated with this study. First, the KITAOKA H et al. study population was small and rather old. The data from control subjects were also absent. Second, levels of serological biomarkers were measured only at 1 point. Third, MMP-9 was not related to echocardiographic findings, which was different to findings from a previous study; 19 this might be due to patient selection. Finally, we have no data that indicate that the specific patients had alternation in their cardiac extracellular matrix; for example, by cardiac magnetic resonance or by serum levels of collagen synthesis and degradation. Although it is not shown that these alternations in MMPs/TIMP were directly related to the changes in cardiac extracellular collagen matrix, we believe that elevated levels of MMPs/TIMP reflect the activation of collagen turnover and fibrosis, as shown in many previous reports in patients with ischemic heart disease, hypertensive heart disease and cardiomyopathy. Further analysis is warranted regarding the relationship between LV remodeling and extracellular collagen matrix regulation in patients with HCM.
